IVONESCIMAB

UNII:	Y0O332CU66
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	IVONESCIMAB
GSRS Full Record:	Y0O332CU66 i

2428381-53-5
AK-112
AK112
IVONESCIMAB [USAN]
Immunoglobulin G1 [240-alanine,241-alanine], anti-(human vascular endothelial growth factor A) (human-Mus musculus monoclonal AK112 γ1-chain) fusion protein with peptide linker (GGGS)4 fusion protein with immunoglobulin anti-(human programmed cell death protein 1) (human-Mus musculus heavy chain V-D-J region) fusion protein with peptide linker (GGGS)4 fusion protein with immunoglobulin anti-(human programmed cell death protein 1) (human-Mus musculus κ-chain V-J region), disulfide with human-Mus musculus monoclonal AK112 κ-chain, dimer
Ivonescimab
Ivonescimab [WHO-DD]
SMT-112
SMT112
immunoglobulin G1-kappa_scFv, anti-[Homo sapiens VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)], each heavy chain being fused to a scFv anti-[Homo sapiens PDCD1 (programmed cell death 1, PD1, PD-1, CD279)], monoclonal antibody, tetravalent, bispecific; gamma1 heavy chain anti-VEGFA fused to scFv anti-PDCD1 (1-719) [gamma1 heavy chain anti-VEGFA (1-453) [VH (Homo sapiens IGHV3-30*02 (76.8%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123) -Homo sapiens IGHG1*01, G1m17,1, G1v14 CH2 A1.3, A1.2 (CH1 K120 (220) (124-221), hinge 1-15 (222-236), CH2 L1.3>A (240), L1.2>A (241) (237-346), CH3 D12 (362), L14 (364) (347-451), CHS (452-453)) (124-453)] -20-mer tetrakis(tetraglycyl-seryl) linker (454-473) -scFv-VH-V-KAPPA anti-PDCD1 (474- 719) [VH (Homo sapiens IGHV3-23*04 (88.7%) -(IGHD) -IGHJ6*01 (90.9%) T123>L (586), CDR-IMGT [8.8.11] (499-506.524-531.570-580)) (474-591) -20- mer tetrakis(tetraglycyl-seryl) linker (592-611) -V-KAPPA Musmus/Homsap (Mus musculus IGKV14-111*01 (86.3%) -IGKJ5*01 (100%)/Homo sapiens IGKV1- 16*01 (80.0%) -IGKJ2*01 (87.5%) Q120>A (711), CDR-IMGT [6.3.9] (638- 643.661-663.700-708)) (612-719)], (226-214')-disulfide with kappa light chain anti-VEGFA (1'-214') [V-KAPPA (Homo sapiens IGKV1-16*01 (88.4%) - IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (232-232'':235-235'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
ivonescimab [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

IVONESCIMAB

Synonyms and Mappings

Resources